{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pilard C"],"funding":["Fonds De La Recherche Scientifique - FNRS"],"pagination":["927-938"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8476530"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["125(7)"],"pubmed_abstract":["In less than a decade, half a dozen immune checkpoint inhibitors have been approved and are currently revolutionising the treatment of many cancer (sub)types. With the clinical evaluation of novel delivery approaches (e.g. oncolytic viruses, cancer vaccines, natural killer cell-mediated cytotoxicity) and combination therapies (e.g. chemo/radio-immunotherapy) as well as the emergence of novel promising targets (e.g. TIGIT, LAG-3, TIM-3), the 'immunotherapy tsunami' is not about to end anytime soon. However, this enthusiasm in the field is somewhat tempered by both the relatively low percentage (<15%) of patients who display an effective anti-cancer immune response and the inability to accurately identify them. Recently, several existing or acquired features/parameters have been shown to imp"],"journal":["British journal of cancer"],"pubmed_title":["Cancer immunotherapy: it's time to better predict patients' response."],"pmcid":["PMC8476530"],"funding_grant_id":["MIS F.4520.20","PDR Televie 7.8507.19"],"pubmed_authors":["Pilard C","Delvenne P","Jerusalem G","Ancion M","Hubert P","Herfs M"],"additional_accession":[]},"is_claimable":false,"name":"Cancer immunotherapy: it's time to better predict patients' response.","description":"In less than a decade, half a dozen immune checkpoint inhibitors have been approved and are currently revolutionising the treatment of many cancer (sub)types. With the clinical evaluation of novel delivery approaches (e.g. oncolytic viruses, cancer vaccines, natural killer cell-mediated cytotoxicity) and combination therapies (e.g. chemo/radio-immunotherapy) as well as the emergence of novel promising targets (e.g. TIGIT, LAG-3, TIM-3), the 'immunotherapy tsunami' is not about to end anytime soon. However, this enthusiasm in the field is somewhat tempered by both the relatively low percentage (<15%) of patients who display an effective anti-cancer immune response and the inability to accurately identify them. Recently, several existing or acquired features/parameters have been shown to imp","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-18T19:39:38.254Z","creation":"2025-04-07T07:22:38.71Z"},"accession":"S-EPMC8476530","cross_references":{"pubmed":["34112949"],"doi":["10.1038/s41416-021-01413-x"]}}